The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Learning The Mechanisms Of Programmed Cell Death And Tumour Suppression To Develop Novel Cancer Therapies
Funder
National Health and Medical Research Council
Funding Amount
$863,910.00
Summary
Our bodies prevent the development of cancer through tumour suppressive processes, which also affect the outcome of cancer therapy. Programmed cell death (apoptosis) is one such process, and defects in apoptosis promote cancer development and impair the response of tumour cells to anti-cancer therapies. My laboratory uses molecular biology and cell biology approaches to investigate the mechanisms of cell death and tumour suppression, partnering with pharma to develop novel cancer therapies.
In a human body, about a million cells are born every second, and a million die by activating a physiological cell death mechanism. If cell death fails to occur, cells accumulate and can develop into cancers. Determining the mechanism and regulation of physiological cell death will provide novel approaches to treat cancers and auto-immune diseases, both of which are characterised by failure of certain cells to die.
Regulation And Mechanisms Of Cell Cycling, Cell Senescence And Cell Death
Funder
National Health and Medical Research Council
Funding Amount
$876,005.00
Summary
Most of our cells are not dividing, but persist in a stable arrested state, yet little is known of the molecular mechanisms that regulate and maintain permanent arrest, or that go wrong when cells start proliferating and turn into cancers. This proposal addresses an area of fundamental, basic biology, that has been largely overlooked. A better understanding of the molecules that regulate cell stability might provide new drug targets so that tumour cell proliferation can be stopped.
The Regulation Of B Cell Differentiation And Survival In Response To Antigen Challenge
Funder
National Health and Medical Research Council
Funding Amount
$763,409.00
Summary
Antibodies are crucial to health and well being but can cause disease if their production is not controlled appropriately. This research program examines the basis of antibody production in normal situations and in situations where it is causing illness, in diseases like system lupus erythematosus (SLE) and in cancers of antibody producing cells called multiple myeloma (MM). The aim is to enable control of the process to achieve better health outcomes and better management of disease.
Programmed cell death regulates the fate of cells during development and adult life. Working at the frontier of biology and chemistry, I lead research programs committed to uncovering cell death processes implicated in a wide range of diseases such as cancer, inflammatory diseases and tissue damage. I will develop novel small molecules that will act as powerful tools to increase our understanding of how cell death participates in these conditions and help develop new drugs to treat them.
Prevention Of Pancreatic Beta Cell Destruction In Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$621,458.00
Summary
Associate Professor Helen Thomas is a molecular and cell biologist with a particular interest in pancreatic islet biology, studying the mechanisms of pancreatic beta-cell destruction in diabetes. The aim of this work is to develop strategies to protect these cells. Such protection will improve our ability to preserve beta-cell mass in type 1 and type 2 diabetes, and after islet transplantation.
A-Prof Roberst is a clinical haematologist caring for patients with blood cancers, who is committed to developing new therapies for currently incurable diseases through laboratory and clinical trial research.
Antigen-presenting cells control immune responses. Different types of these cells do different jobs and affect different diseases. We wish to control these processes by determining how the cells live and die. In particular we are interested in controlling the local immune responses during rejection of islet transplantation, which can cure type 1 diabetes.
Targeting Host Pathogen Interactions And Signalling Networks To Promote Death Of Infected Cells And Facilitate Pathogen Clearance
Funder
National Health and Medical Research Council
Summary
Preclinical models of infectious diseases including hepatitis B, HIV, tuberculosis and human herpes virus infections will be used to understand how pathogens interact with host cells. With this understanding we aim to identify which host cell signalling pathways play a critical role in limiting or faciliating pathogen persistence. After identifying the important cellular pathways we aim to target these host cell signalling components with clinical stage drugs to promote pathogen clearance.
A common characteristic of cancer is the failure of cells to die when they normally would. One of the problems with many cancer therapies is that they rely on the integrity of signalling pathways to the normal ‘death machinery’ of the cell to do their job. By understanding how the molecular death machine operates we are fashioning new drugs that can target it directly, thus bypassing the very pathways that are so frequently disrupted in tumour cells.